Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06799247 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 30 days later Nov 30, 2026 → Dec 30, 2026
See other at-risk trials from Cartesian Therapeutics

Record History

  1. Enrollment closed, study ongoing Primary completion pushed from Nov 30, 2026 to Dec 30, 2026 · Final enrollment: 128 participants (planned 100) · Site details revised at 34 of 34 sitesv17 Show 3 more changesShow less
    • Primary completion pushed from Nov 30, 2026 to Dec 30, 2026
    • Final enrollment: 128 participants (planned 100)
    • Site details revised at 34 of 34 sites
  2. Study sites: 25 to 34v16
  3. Study sites: 21 to 25v15
  4. Study sites: 19 to 21v14
  5. Study sites: 18 to 19v13
Show 11 earlier versionsHide 11 earlier versions
  1. Study sites: 15 to 18v12
  2. Study sites: 13 to 15v11
  3. Study sites: 8 to 13v10
  4. Study sites: 4 to 8v9
  5. Study sites: 2 to 4v8
  6. Study sites: 1 to 2v7
  7. Start date changed from estimate of Apr 11, 2025 to May 6, 2025v6
  8. Trial status: Not Yet Recruiting to Recruiting Start date: Feb 28, 2025 to Apr 11, 2025 · Study sites: 0 to 1v5 Show 2 more changesShow less
    • Start date: Feb 28, 2025 to Apr 11, 2025
    • Study sites: 0 to 1
  9. Primary completion date: Apr 28, 2026 to Nov 30, 2026 Trial status: Recruiting to Not Yet Recruiting · Study sites: 1 to 0 · Completion date: Apr 28, 2026 to Sep 30, 2027v4 Show 3 more changesShow less
    • Trial status: Recruiting to Not Yet Recruiting
    • Study sites: 1 to 0
    • Completion date: Apr 28, 2026 to Sep 30, 2027
  10. Study site revisedv3 See this version in full on ClinicalTrials.gov ↗
  11. Re-verified, no change to tracked fieldsv2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The AURORA Study is evaluating the safety, tolerability, and efficacy of an investigational mRNA CAR T-cell therapy known as Descartes-08 in adults with acetylcholine receptor autoantibody -positive generalized myasthenia gravis. Part 1 of the study will last around 6 months. For eligible participants, Part 2 will last around 8 months.
Trial Details
NCT Number NCT06799247
Lead Sponsor Cartesian Therapeutics
Conditions Myasthaenia Gravis
Enrollment 128 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov